Pediatric Nephrology

, 26:1789 | Cite as

Bartter- and Gitelman-like syndromes: salt-losing tubulopathies with loop or DCT defects

  • Hannsjörg W. SeyberthEmail author
  • Karl P. Schlingmann
Educational Review


Salt-losing tubulopathies with secondary hyperaldosteronism (SLT) comprise a set of well-defined inherited tubular disorders. Two segments along the distal nephron are primarily involved in the pathogenesis of SLTs: the thick ascending limb of Henle’s loop, and the distal convoluted tubule (DCT). The functions of these pre- and postmacula densa segments are quite distinct, and this has a major impact on the clinical presentation of loop and DCT disorders – the Bartter- and Gitelman-like syndromes. Defects in the water-impermeable thick ascending limb, with its greater salt reabsorption capacity, lead to major salt and water losses similar to the effect of loop diuretics. In contrast, defects in the DCT, with its minor capacity of salt reabsorption and its crucial role in fine-tuning of urinary calcium and magnesium excretion, provoke more chronic solute imbalances similar to the effects of chronic treatment with thiazides. The most severe disorder is a combination of a loop and DCT disorder similar to the enhanced diuretic effect of a co-medication of loop diuretics with thiazides. Besides salt and water supplementation, prostaglandin E2-synthase inhibition is the most effective therapeutic option in polyuric loop disorders (e.g., pure furosemide and mixed furosemide–amiloride type), especially in preterm infants with severe volume depletion. In DCT disorders (e.g., pure thiazide and mixed thiazide–furosemide type), renin–angiotensin–aldosterone system (RAAS) blockers might be indicated after salt, potassium, and magnesium supplementation are deemed insufficient. It appears that in most patients with SLT, a combination of solute supplementation with some drug treatment (e.g., indomethacin) is needed for a lifetime.


Bartter syndrome Gitelman syndrome Salt-losing tubulopathies Classification Prostaglandins Secondary hyperaldosteronism Differential diagnosis Treatment 



  1. 1.
    Schnermann J (1998) Juxtaglomerular cell complex in the regulation of renal salt excretion. Am J Physiol 274:R263–R279PubMedGoogle Scholar
  2. 2.
    Deng A, Wead LM, Blantz RC (2004) Temporal adaptation of tubuloglomerular feedback: effects of COX-2. Kidney Int 66:2348–2353PubMedCrossRefGoogle Scholar
  3. 3.
    Peti-Peterdi J, Harris RC (2010) Macula densa sensing and signaling mechanisms of renin release. J Am Soc Nephrol 21:1093–1096PubMedCrossRefGoogle Scholar
  4. 4.
    Schlingmann KP, Weber S, Peters M, Niemann Nejsum L, Vitzthum H, Klingel K, Kratz M, Haddad E, Ristoff E, Dinour D, Syrrou M, Nielsen S, Sassen M, Waldegger S, Seyberth HW, Konrad M (2002) Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. Nat Genet 31:166–170PubMedCrossRefGoogle Scholar
  5. 5.
    Nijenhuis T, Vallon V, van der Kemp AW, Loffing J, Hoenderop JG, Bindels RJ (2005) Enhanced passive Ca2+ reabsorption and reduced Mg2+ channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia. J Clin Invest 115:1651–1658PubMedCrossRefGoogle Scholar
  6. 6.
    Bartter F, Pronove P, Gill J Jr, MacCardle R (1962) Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. A new syndrome. Am J Med 33:811–828PubMedCrossRefGoogle Scholar
  7. 7.
    Gitelman HJ, Graham JB, Welt LG (1966) A new familial disorder characterized by hypokalemia and hypomagnesemia. Trans Assoc Am Physicians 79:221–235PubMedGoogle Scholar
  8. 8.
    Fanconi A, Schachenmann G, Nussli R, Prader A (1971) Chronic hypokalaemia with growth retardation, normotensive hyperrenin-hyperaldosteronism ("Bartter's syndrome"), and hypercalciuria. Report of two cases with emphasis on natural history and on catch-up growth during treatment. Helv Paediatr Acta 26:144–163PubMedGoogle Scholar
  9. 9.
    Ohlsson A, Sieck U, Cumming W, Akhtar M, Serenius F (1984) A variant of Bartter's syndrome. Bartter's syndrome associated with hydramnios, prematurity, hypercalciuria and nephrocalcinosis. Acta Paediatr Scand 73:868–874PubMedCrossRefGoogle Scholar
  10. 10.
    Seyberth HW, Rascher W, Schweer H, Kuhl PG, Mehls O, Scharer K (1985) Congenital hypokalemia with hypercalciuria in preterm infants: a hyperprostaglandinuric tubular syndrome different from Bartter syndrome. J Pediatr 107:694–701PubMedCrossRefGoogle Scholar
  11. 11.
    Seyberth HW, Koniger SJ, Rascher W, Kuhl PG, Schweer H (1987) Role of prostaglandins in hyperprostaglandin E syndrome and in selected renal tubular disorders. Pediatr Nephrol 1:491–497PubMedCrossRefGoogle Scholar
  12. 12.
    Seyberth HW (2008) An improved terminology and classification of Bartter-like syndromes. Nat Clin Pract Nephrol 4:560–567PubMedCrossRefGoogle Scholar
  13. 13.
    Kurtz I (1998) Molecular pathogenesis of Bartter's and Gitelman's syndromes. Kidney Int 54:1396–1410PubMedCrossRefGoogle Scholar
  14. 14.
    Seyberth H, Soergel M, Koeckerling A (1998) Hypokalaemic tubular disorders: the hyperprostaglandin E syndrome and Gitelman-Bartter syndrome. Oxford University Press, OxfordGoogle Scholar
  15. 15.
    Reinalter SC, Jeck N, Peters M, Seyberth HW (2004) Pharmacotyping of hypokalaemic salt-losing tubular disorders. Acta Physiol Scand 181:513–521PubMedCrossRefGoogle Scholar
  16. 16.
    Unwin RJ, Capasso G (2006) Bartter's and Gitelman's syndromes: their relationship to the actions of loop and thiazide diuretics. Curr Opin Pharmacol 6:208–213PubMedCrossRefGoogle Scholar
  17. 17.
    Peters M, Jeck N, Reinalter S, Leonhardt A, Tönshoff B, Klaus GG, Konrad M, Seyberth HW (2002) Clinical presentation of genetically defined patients with hypokalemic salt-losing tubulopathies. Am J Med 112:183–190PubMedCrossRefGoogle Scholar
  18. 18.
    Hufnagle KG, Khan SN, Penn D, Cacciarelli A, Williams P (1982) Renal calcifications: a complication of long-term furosemide therapy in preterm infants. Pediatrics 70:360–363PubMedGoogle Scholar
  19. 19.
    Simon DB, Karet FE, Hamdan JM, DiPietro A, Sanjad SA, Lifton RP (1996) Bartter's syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. Nat Genet 13:183–188PubMedCrossRefGoogle Scholar
  20. 20.
    Simon DB, Karet FE, Rodriguez-Soriano J, Hamdan JH, DiPietro A, Trachtman H, Sanjad SA, Lifton RP (1996) Genetic heterogeneity of Bartter's syndrome revealed by mutations in the K+ channel, ROMK. Nat Genet 14:152–156PubMedCrossRefGoogle Scholar
  21. 21.
    Karolyi L, International Study Group for Bartter-like Syndromes (1997) Mutations in the gene encoding the inwardly-rectifying renal potassium channel, ROMK, cause the antenatal variant of Bartter syndrome: evidence for genetic heterogeneity. [published erratum appears in Hum Mol Genet 1997 Apr;6(4):650]. Hum Mol Genet 6:17–26CrossRefGoogle Scholar
  22. 22.
    Hollifield JW (1989) Thiazide treatment of systemic hypertension: effects on serum magnesium and ventricular ectopic activity. Am J Cardiol 63:22G–25GPubMedCrossRefGoogle Scholar
  23. 23.
    Simon DB, Nelson-Williams C, Bia MJ, Ellison D, Karet FE, Molina AM, Vaara I, Iwata F, Cushner HM, Koolen M, Gainza FJ, Gitleman HJ, Lifton RP (1996) Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nat Genet 12:24–30PubMedCrossRefGoogle Scholar
  24. 24.
    Jeck N, Schlingmann KP, Reinalter SC, Kömhoff M, Peters M, Waldegger S, Seyberth HW (2005) Salt handling in the distal nephron: lessons learned from inherited human disorders. Am J Physiol Regul Integr Comp Physiol 288:R782–R795PubMedCrossRefGoogle Scholar
  25. 25.
    Cruz DN, Shaer AJ, Bia MJ, Lifton RP, Simon DB (2001) Gitelman's syndrome revisited: an evaluation of symptoms and health-related quality of life. Kidney Int 59:710–717PubMedCrossRefGoogle Scholar
  26. 26.
    Riveira-Munoz E, Chang Q, Godefroid N, Hoenderop JG, Bindels RJ, Dahan K, Devuyst O (2007) Transcriptional and functional analyses of SLC12A3 mutations: new clues for the pathogenesis of Gitelman syndrome. J Am Soc Nephrol 18:1271–1283PubMedCrossRefGoogle Scholar
  27. 27.
    Knoers NV, Levtchenko EN (2008) Gitelman syndrome. Orphanet J Rare Dis 3:22PubMedCrossRefGoogle Scholar
  28. 28.
    Smilde TJ, Haverman JF, Schipper P, Hermus AR, van Liebergen FJ, Jansen JL, Kloppenborg PW, Koolen MI (1994) Familial hypokalemia/hypomagnesemia and chondrocalcinosis. J Rheumatol 21:1515–1519PubMedGoogle Scholar
  29. 29.
    Lin SH, Cheng NL, Hsu YJ, Halperin ML (2004) Intrafamilial phenotype variability in patients with Gitelman syndrome having the same mutations in their thiazide-sensitive sodium/chloride cotransporter. Am J Kidney Dis 43:304–312PubMedCrossRefGoogle Scholar
  30. 30.
    Simon DB, Bindra RS, Mansfield TA, Nelson-Williams C, Mendonca E, Stone R, Schurman S, Nayir A, Alpay H, Bakkaloglu A, Rodriguez-Soriano J, Morales JM, Sanjad SA, Taylor CM, Pilz D, Brem A, Trachtman H, Griswold W, Richard GA, John E, Lifton RP (1997) Mutations in the chloride channel gene, CLCNKB, cause Bartter's syndrome type III. Nat Genet 17:171–178PubMedCrossRefGoogle Scholar
  31. 31.
    Konrad M, Vollmer M, Lemmink HH, van den Heuvel LP, Jeck N, Vargas-Poussou R, Lakings A, Ruf R, Deschenes G, Antignac C, Guay-Woodford L, Knoers NV, Seyberth HW, Feldmann D, Hildebrandt F (2000) Mutations in the chloride channel gene CLCNKB as a cause of classic Bartter syndrome. J Am Soc Nephrol 11:1449–1459PubMedGoogle Scholar
  32. 32.
    Schlingmann KP, Konrad M, Jeck N, Waldegger P, Reinalter SC, Holder M, Seyberth HW, Waldegger S (2004) Salt wasting and deafness resulting from mutations in two chloride channels. N Engl J Med 350:1314–1319PubMedCrossRefGoogle Scholar
  33. 33.
    Kramer BK, Bergler T, Stoelcker B, Waldegger S (2008) Mechanisms of Disease: the kidney-specific chloride channels ClCKA and ClCKB, the Barttin subunit, and their clinical relevance. Nat Clin Pract Nephrol 4:38–46PubMedCrossRefGoogle Scholar
  34. 34.
    Brochard K, Boyer O, Blanchard A, Loirat C, Niaudet P, Macher MA, Deschenes G, Bensman A, Decramer S, Cochat P, Morin D, Broux F, Caillez M, Guyot C, Novo R, Jeunemaitre X, Vargas-Poussou R (2009) Phenotype-genotype correlation in antenatal and neonatal variants of Bartter syndrome. Nephrol Dial Transplant 24:1455–1464PubMedCrossRefGoogle Scholar
  35. 35.
    Nozu K, Iijima K, Kanda K, Nakanishi K, Yoshikawa N, Satomura K, Kaito H, Hashimura Y, Ninchoji T, Komatsu H, Kamei K, Miyashita R, Kugo M, Ohashi H, Yamazaki H, Mabe H, Otsubo A, Igarashi T, Matsuo M (2010) The pharmacological characteristics of molecular-based inherited salt-losing tubulopathies. J Clin Endocrinol Metab 95:E511–E518PubMedCrossRefGoogle Scholar
  36. 36.
    Jeck N, Konrad M, Peters M, Weber S, Bonzel KE, Seyberth HW (2000) Mutations in the chloride channel gene, CLCNKB, leading to a mixed Bartter-Gitelman phenotype. Pediatr Res 48:754–758PubMedCrossRefGoogle Scholar
  37. 37.
    Zelikovic I, Szargel R, Hawash A, Labay V, Hatib I, Cohen N, Nakhoul F (2003) A novel mutation in the chloride channel gene, CLCNKB, as a cause of Gitelman and Bartter syndromes. Kidney Int 63:24–32PubMedCrossRefGoogle Scholar
  38. 38.
    Bockenhauer D, Feather S, Stanescu HC, Bandulik S, Zdebik AA, Reichold M, Tobin J, Lieberer E, Sterner C, Landoure G, Arora R, Sirimanna T, Thompson D, Cross JH, van't Hoff W, Al Masri O, Tullus K, Yeung S, Anikster Y, Klootwijk E, Hubank M, Dillon MJ, Heitzmann D, Arcos-Burgos M, Knepper MA, Dobbie A, Gahl WA, Warth R, Sheridan E, Kleta R (2009) Epilepsy, ataxia, sensorineural deafness, tubulopathy, and KCNJ10 mutations. N Engl J Med 360:1960–1970PubMedCrossRefGoogle Scholar
  39. 39.
    Scholl UI, Choi M, Liu T, Ramaekers VT, Hausler MG, Grimmer J, Tobe SW, Farhi A, Nelson-Williams C, Lifton RP (2009) Seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance (SeSAME syndrome) caused by mutations in KCNJ10. Proc Natl Acad Sci USA 106:5842–5847PubMedCrossRefGoogle Scholar
  40. 40.
    Ito M, Inanobe A, Horio Y, Hibino H, Isomoto S, Ito H, Mori K, Tonosaki A, Tomoike H, Kurachi Y (1996) Immunolocalization of an inwardly rectifying K+ channel, K(AB)-2 (Kir4.1), in the basolateral membrane of renal distal tubular epithelia. FEBS Lett 388:11–15PubMedCrossRefGoogle Scholar
  41. 41.
    Birkenhager R, Otto E, Schurmann MJ, Vollmer M, Ruf EM, Maier-Lutz I, Beekmann F, Fekete A, Omran H, Feldmann D, Milford DV, Jeck N, Konrad M, Landau D, Knoers NV, Antignac C, Sudbrak R, Kispert A, Hildebrandt F (2001) Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure. Nat Genet 29:310–314PubMedCrossRefGoogle Scholar
  42. 42.
    Jeck N, Reinalter SC, Henne T, Marg W, Mallmann R, Pasel K, Vollmer M, Klaus G, Leonhardt A, Seyberth HW, Konrad M (2001) Hypokalemic salt-losing tubulopathy with chronic renal failure and sensorineural deafness. Pediatrics 108:E5PubMedCrossRefGoogle Scholar
  43. 43.
    Bichet DG (2006) Hereditary polyuric disorders: new concepts and differential diagnosis. Semin Nephrol 26:224–233PubMedCrossRefGoogle Scholar
  44. 44.
    Finer G, Shalev H, Birk OS, Galron D, Jeck N, Sinai-Treiman L, Landau D (2003) Transient neonatal hyperkalemia in the antenatal (ROMK defective) Bartter syndrome. J Pediatr 142:318–323PubMedCrossRefGoogle Scholar
  45. 45.
    Nozu K, Fu XJ, Kaito H, Kanda K, Yokoyama N, Przybyslaw Krol R, Nakajima T, Kajiyama M, Iijima K, Matsuo M (2007) A novel mutation in KCNJ1 in a Bartter syndrome case diagnosed as pseudohypoaldosteronism. Pediatr Nephrol 22:1219–1223PubMedCrossRefGoogle Scholar
  46. 46.
    Pressler CA, Heinzinger J, Jeck N, Waldegger P, Pechmann U, Reinalter S, Konrad M, Beetz R, Seyberth HW, Waldegger S (2006) Late-onset manifestation of antenatal Bartter syndrome as a result of residual function of the mutated renal Na+−K+−2Cl- co-transporter. J Am Soc Nephrol 17:2136–2142PubMedCrossRefGoogle Scholar
  47. 47.
    Schurman SJ, Shoemaker LR (2000) Bartter and Gitelman syndromes. Adv Pediatr 47:223–248PubMedGoogle Scholar
  48. 48.
    Rodriguez-Soriano J, Vallo A, Castillo G, Oliveros R (1981) Renal handling of water and sodium in infancy and childhood: a study using clearance methods during hypotonic saline diuresis. Kidney Int 20:700–704PubMedCrossRefGoogle Scholar
  49. 49.
    Colussi G, Bettinelli A, Tedeschi S, De Ferrari ME, Syren ML, Borsa N, Mattiello C, Casari G, Bianchetti MG (2007) A thiazide test for the diagnosis of renal tubular hypokalemic disorders. Clin J Am Soc Nephrol 2:454–460PubMedCrossRefGoogle Scholar
  50. 50.
    Sassen MC, Jeck N, Klaus G (2007) Can renal tubular hypokalemic disorders be accurately diagnosed on the basis of the diuretic response to thiazide? Nat Clin Pract Nephrol 3:528–529PubMedCrossRefGoogle Scholar
  51. 51.
    Pollak MR, Brown EM, Estep HL, McLaine PN, Kifor O, Park J, Hebert SC, Seidman CE, Seidman JG (1994) Autosomal dominant hypocalcaemia caused by a Ca(2+)-sensing receptor gene mutation. Nat Genet 8:303–307PubMedCrossRefGoogle Scholar
  52. 52.
    Hebert SC (2003) Bartter syndrome. Curr Opin Nephrol Hypertens 12:527–532PubMedCrossRefGoogle Scholar
  53. 53.
    Vargas-Poussou R, Huang C, Hulin P, Houillier P, Jeunemaitre X, Paillard M, Planelles G, Dechaux M, Miller RT, Antignac C (2002) Functional characterization of a calcium-sensing receptor mutation in severe autosomal dominant hypocalcemia with a Bartter-like syndrome. J Am Soc Nephrol 13:2259–2266PubMedCrossRefGoogle Scholar
  54. 54.
    Watanabe S, Fukumoto S, Chang H, Takeuchi Y, Hasegawa Y, Okazaki R, Chikatsu N, Fujita T (2002) Association between activating mutations of calcium-sensing receptor and Bartter's syndrome. Lancet 360:692–694PubMedCrossRefGoogle Scholar
  55. 55.
    Casatta L, Ferraccioli GF, Bartoli E (1997) Hypokalaemic alkalosis, acquired Gitelman's and Bartter's syndrome in chronic sialoadenitis. Br J Rheumatol 36:1125–1128PubMedCrossRefGoogle Scholar
  56. 56.
    Besbas N, Ozaltin F, Jeck N, Seyberth H, Ludwig M (2005) CLCN5 mutation (R347X) associated with hypokalaemic metabolic alkalosis in a Turkish child: an unusual presentation of Dent's disease. Nephrol Dial Transplant 20:1476–1479PubMedCrossRefGoogle Scholar
  57. 57.
    Yu TM, Lin SH, Ya-Wen C, Wen MC, Chen YH, Cheng CH, Chen CH, Chin CS, Shu KH (2009) A syndrome resembling Bartter's syndrome in sarcoidosis. Nephrol Dial Transplant 24:667–669PubMedCrossRefGoogle Scholar
  58. 58.
    Emma F, Pizzini C, Tessa A, Di Giandomenico S, Onetti-Muda A, Santorelli FM, Bertini E, Rizzoni G (2006) "Bartter-like" phenotype in Kearns-Sayre syndrome. Pediatr Nephrol 21:355–360PubMedCrossRefGoogle Scholar
  59. 59.
    Caltik A, Akyuz SG, Erdogan O, Bulbul M, Demircin G (2010) Rare presentation of cystinosis mimicking Bartter's syndrome: reports of two patients and review of the literature. Ren Fail 32:277–280PubMedCrossRefGoogle Scholar
  60. 60.
    Chrispal A, Boorugu H, Prabhakar AT, Moses V (2009) Amikacin-induced type 5 Bartter-like syndrome with severe hypocalcemia. J Postgrad Med 55:208–210PubMedCrossRefGoogle Scholar
  61. 61.
    Talosi G, Katona M, Turi S (2007) Side-effects of long-term prostaglandin E(1) treatment in neonates. Pediatr Int 49:335–340PubMedCrossRefGoogle Scholar
  62. 62.
    Panichpisal K, Angulo-Pernett F, Selhi S, Nugent KM (2006) Gitelman-like syndrome after cisplatin therapy: a case report and literature review. BMC Nephrol 7:10PubMedCrossRefGoogle Scholar
  63. 63.
    Bartter F (1980) On the pathogenesis of Bartter’s syndrome. Miner Electrolyte Metab 3:61–65Google Scholar
  64. 64.
    Rodriguez-Soriano J (1999) Tubular disorders of electrolyte regulation. In: Barratt TM, Avner ED, Harmon WE (eds) Pediatric nephrology. Lippincott Williams & Wilkins, Baltimore, pp 545–563Google Scholar
  65. 65.
    Nüsing RM, Seyberth HW (2004) The role of cyclooxygenases and prostanoid receptorsin furosemide-like salt losing tubulopathy: the hyperprostaglandin E syndrome. Acta Physiol Scand 181:523–528PubMedCrossRefGoogle Scholar
  66. 66.
    Nüsing RM, Treude A, Weissenberger C, Jensen B, Bek M, Wagner C, Narumiya S, Seyberth HW (2005) Dominant role of prostaglandin E2 EP4 receptor in furosemide-induced salt-losing tubulopathy: a model for hyperprostaglandin E syndrome/antenatal Bartter syndrome. J Am Soc Nephrol 16:2354–2362PubMedCrossRefGoogle Scholar
  67. 67.
    Kömhoff M, Tekesin I, Peters M, Leonhard A, Seyberth HW (2005) Perinatal management of a preterm neonate affected by hyperprostaglandin E2 syndrome (HPS). Acta Paediatr 94:1690–1693PubMedCrossRefGoogle Scholar
  68. 68.
    Seidel C, Reinalter S, Seyberth HW, Scharer K (1995) Pre-pubertal growth in the hyperprostaglandin E syndrome. Pediatr Nephrol 9:723–728PubMedCrossRefGoogle Scholar
  69. 69.
    Liaw LC, Banerjee K, Coulthard MG (1999) Dose related growth response to indometacin in Gitelman syndrome. Arch Dis Child 81:508–510PubMedCrossRefGoogle Scholar
  70. 70.
    Gladziwa U, Schwarz R, Gitter AH, Bijman J, Seyberth H, Beck F, Ritz E, Gross P (1995) Chronic hypokalaemia of adults: Gitelman's syndrome is frequent but classical Bartter's syndrome is rare. Nephrol Dial Transplant 10:1607–1613PubMedGoogle Scholar
  71. 71.
    European Medicine Agency (2006) List of paediatric needs in nephrology as established by the Paediatric Working Party
  72. 72.
    Hene RJ, Koomans HA, Dorhout Mees EJ, van de Stolpe A, Verhoef GE, Boer P (1987) Correction of hypokalemia in Bartter's syndrome by enalapril. Am J Kidney Dis 9:200–205PubMedGoogle Scholar
  73. 73.
    van de Stolpe A, Verhoef GE, Hene RJ, Koomans HA, van der Vijver JC (1987) Total body potassium in Bartter's syndrome before and during treatment with enalapril. Nephron 45:122–125PubMedCrossRefGoogle Scholar
  74. 74.
    Bell DS (2009) Successful utilization of aliskiren, a direct renin inhibitor in Bartter syndrome. South Med J 102:413–415PubMedCrossRefGoogle Scholar
  75. 75.
    Bettinelli A, Borsa N, Bellantuono R, Syren ML, Calabrese R, Edefonti A, Komninos J, Santostefano M, Beccaria L, Pela I, Bianchetti MG, Tedeschi S (2007) Patients with biallelic mutations in the chloride channel gene CLCNKB: long-term management and outcome. Am J Kidney Dis 49:91–98PubMedCrossRefGoogle Scholar
  76. 76.
    Puricelli E, Bettinelli A, Borsa N, Sironi F, Mattiello C, Tammaro F, Tedeschi S, Bianchetti MG (2010) Long-term follow-up of patients with Bartter syndrome type I and II. Nephrol Dial Transplant 25:2976–2981PubMedCrossRefGoogle Scholar
  77. 77.
    Phillips DR, Ahmad KI, Waller SJ, Meisner P, Karet FE (2006) A serum potassium level above 10 mmol/l in a patient predisposed to hypokalemia. Nat Clin Pract Nephrol 2:340–346, quiz 347PubMedCrossRefGoogle Scholar
  78. 78.
    Kleta R, Bockenhauer D (2006) Bartter syndromes and other salt-losing tubulopathies. Nephron Physiol 104:p73–p80PubMedCrossRefGoogle Scholar
  79. 79.
    Chadha V, Alon US (2009) Hereditary renal tubular disorders. Semin Nephrol 29:399–411PubMedCrossRefGoogle Scholar
  80. 80.
    Leonhardt A, Timmermanns G, Roth B, Seyberth HW (1992) Calcium homeostasis and hypercalciuria in hyperprostaglandin E syndrome [see comments]. J Pediatr 120:546–554PubMedCrossRefGoogle Scholar
  81. 81.
    Reinalter SC, Gröne HJ, Konrad M, Seyberth HW, Klaus G (2001) Evaluation of long-term treatment with indomethacin in hereditary hypokalemic salt-losing tubulopathies. J Pediatr 139:398–406PubMedCrossRefGoogle Scholar
  82. 82.
    Reinalter S, Devlieger H, Proesmans W (1998) Neonatal Bartter syndrome: spontaneous resolution of all signs and symptoms. Pediatr Nephrol 12:186–188PubMedCrossRefGoogle Scholar
  83. 83.
    Schachter AD, Arbus GS, Alexander RJ, Balfe JW (1998) Non-steroidal anti-inflammatory drug-associated nephrotoxicity in Bartter syndrome. Pediatr Nephrol 12:775–777PubMedCrossRefGoogle Scholar
  84. 84.
    Vaisbich MH, Fujimura MD, Koch VH (2004) Bartter syndrome: benefits and side effects of long-term treatment. Pediatr Nephrol 19:858–863PubMedCrossRefGoogle Scholar
  85. 85.
    Kleta R, Basoglu C, Kuwertz-Broking E (2000) New treatment options for Bartter's syndrome. N Engl J Med 343:661–662PubMedCrossRefGoogle Scholar
  86. 86.
    Nüsing RM, Reinalter SC, Peters M, Kömhoff M, Seyberth HW (2001) Pathogenetic role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome: therapeutic use of the cyclooxygenase-2 inhibitor nimesulide. Clin Pharmacol Ther 70:384–390PubMedGoogle Scholar
  87. 87.
    Reinalter SC, Jeck N, Brochhausen C, Watzer B, Nüsing RM, Seyberth HW, Komhoff M (2002) Role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome. Kidney Int 62:253–260PubMedCrossRefGoogle Scholar
  88. 88.
    Kömhoff M, Klaus G, Nazarowa S, Reinalter SC, Seyberth HW (2006) Increased systolic blood pressure with rofecoxib in congenital furosemide-like salt loss. Nephrol Dial Transplant 21:1833–1837PubMedCrossRefGoogle Scholar
  89. 89.
    Scognamiglio R, Negut C, Calo LA (2007) Aborted sudden cardiac death in two patients with Bartter's/Gitelman's syndromes. Clin Nephrol 67:193–197PubMedGoogle Scholar
  90. 90.
    Malafronte C, Borsa N, Tedeschi S, Syren ML, Stucchi S, Bianchetti MG, Achilli F, Bettinelli A (2004) Cardiac arrhythmias due to severe hypokalemia in a patient with classic Bartter disease. Pediatr Nephrol 19:1413–1415PubMedCrossRefGoogle Scholar
  91. 91.
    Pachulski RT, Lopez F, Sharaf R (2005) Gitelman's not-so-benign syndrome. N Engl J Med 353:850–851PubMedCrossRefGoogle Scholar
  92. 92.
    Arizona Center for Education and Research on Therapeutics (2010) QT drug list by risk groups: Drugs that prolong the QT interval and/or induce torsades de points ventricular arrhythmia
  93. 93.
    Rudin A (1988) Bartter's syndrome. A review of 28 patients followed for 10 years. Acta Med Scand 224:165–171PubMedCrossRefGoogle Scholar

Copyright information

© IPNA 2011

Authors and Affiliations

  • Hannsjörg W. Seyberth
    • 1
    • 2
    Email author
  • Karl P. Schlingmann
    • 3
  1. 1.Department of Pediatrics and Adolescent MedicinePhilipps UniversityMarburgGermany
  2. 2.LandauGermany
  3. 3.Department of General PediatricsUniversity Children’s HospitalMünsterGermany

Personalised recommendations